Headquartered in Houston TX but with Lab facailites in Aurora, CO (site of first SBIR award) Greffex is a structured around activities in the arenas of vaccine and gene therapy. A genetic engineering company, the firm is developing a plug and play vaccine platform that delivers rapid time-to-market, cost efficiency, efficacy and safety through the use of proprietary clean viral vectors. A privately held, multi-national company established in 1999, Greffex has developed a novel genetic platform for the development and production of vaccines. The firm's proprietary GREVAX⢠Universal Platform delivers vaccines in a fast, affordable and efficient manner. Once a pathogen has been identified, Greffexâs team designs and produces a GREVAX⢠vaccine - often in weeks. The state-of-the-art flexibility of GREVAX⢠Universal Platform makes it the ideal delivery vehicle for vaccines against a wide variety of infectious disease, including but not limited to Pandemic Influenza strains, Anthrax and Dengue Fever, as well as Malaria, Hepatitis C, Respiratory Syncytial Virus (RSV), Ebola, HPV, Plague, Tuberculosis and a host of other vaccine candidates. Pre-dating their first SBIR Involvement, in 2019, Greffex had been awarded an $18.9 million contract from the National Institute of Allergy and Infectious Diseases, part of NIH - enabling GREFFEX to develop and exploit its GreVac(TM) Plug-And-Play Technology to expedite the production of vaccine candidates for biodefense and emerging infectious diseases to target infectious threats, whether natural or ma
